PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-32.96%
Both companies show declining cash positions (-32.96% vs TRAW's -2.60%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-32.96%
Cash + STI yoy ≥ 1.5x TRAW's -2.60%. David Dodd might see it as a strategic cash buffer advantage. Evaluate deployment plans.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-31.20%
≥ 1.5x TRAW's -2.62%. David Dodd might see a short-term liquidity advantage or potential underutilized capital.
-7.82%
Below half TRAW's -18.60%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
305.95%
Below half of TRAW's -17.02%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
-28.88%
≥ 1.5x TRAW's -2.74%. David Dodd notes a larger balance sheet expansion. Confirm it's not overleveraged.
-28.35%
Less than half of TRAW's 5.07%. David Dodd sees a more disciplined AP approach or lower volume.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-25.97%
Less than half of TRAW's 44.02%. David Dodd sees fewer expansions in other current obligations.
-23.54%
Above 1.5x TRAW's -0.19%. Michael Burry sees a red flag for liquidity risk vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-23.54%
1.25-1.5x TRAW's -18.72%. Martin Whitman is wary of bigger liability expansions.
2.39%
Less than half of TRAW's 45.59%. David Dodd sees fewer share issuances vs. competitor.
-4.88%
≥ 1.5x TRAW's -0.75%. David Dodd sees higher yoy retained profits than competitor.
-7.49%
Less than half of TRAW's 61.54%. David Dodd sees fewer intangible or market-driven swings than competitor.
No Data
No Data available this quarter, please select a different quarter.
-31.10%
Below half TRAW's 89.04%. Michael Burry sees potential underperformance in building shareholder capital.
-28.88%
≥ 1.5x TRAW's -2.74%. David Dodd sees faster overall balance sheet growth than competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
32.96%
Above 1.5x TRAW's 2.60%. Michael Burry sees a major gap in net debt growth. Check coverage and liquidity.